Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. (Nov 2018)
Breast cancer is the second leading cause of death among women.
Although early diagnosis and development of new treatments have improved their prognosis, many patients present innate or acquired resistance to current therapies. New therapeutic approaches are therefore warranted for the management of this disease. Extensive preclinical research has demonstrated that cannabinoids, the active ingredients of Cannabis sativa, trigger antitumor responses in different models of cancer.